MBIO - Mustang Bio Inc Stock Price, Fair Value and News

$0.170.00 (0.00%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MBIO Price Action

Last 7 days

-10.5%

Last 30 days

-19.0%

Last 90 days

-22.7%

Trailing 12 Months

-86.3%

MBIO RSI Chart

MBIO Valuation

Market Cap

6.3M

Price/Earnings (Trailing)

-0.27

Price/Sales (Trailing)

11.58

Price/Free Cashflow

-0.31

MBIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MBIO Fundamentals

MBIO Revenue

Revenue (TTM)

541.0K

Rev. Growth (Yr)

-65.22%

Rev. Growth (Qtr)

-84.71%

MBIO Earnings

Earnings (TTM)

-23.4M

Earnings Growth (Yr)

85.98%

Earnings Growth (Qtr)

82.8%

MBIO Profitability

Return on Equity

270.52%

Return on Assets

-325.54%

Free Cashflow Yield

-324.31%

MBIO Investor Care

Shares Dilution (1Y)

353.08%

Diluted EPS (TTM)

-1.56

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.1M	922.0K	541.0K	0
2023	1.8M	2.1M	1.6M	0
2022	367.0K	310.0K	894.0K	1.4M
2021	579.0K	522.0K	435.0K	0
2020	1.4M	1.1M	885.0K	708.0K
2019	575.0K	815.0K	1.1M	1.3M
2018	560.5K	573.5K	567.5K	569.0K
2017	138.1K	260.3K	382.4K	504.5K
2016	0	0	0	16.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Mustang Bio Inc

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

CEO	Dr. Manuel Litchman M.D.
WEBSITE	mustangbio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	113

Mustang Bio Inc Frequently Asked Questions

What is the ticker symbol for Mustang Bio Inc? What does MBIO stand for in stocks?

MBIO is the stock ticker symbol of Mustang Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mustang Bio Inc (MBIO)?

As of Fri Dec 20 2024, market cap of Mustang Bio Inc is 6.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MBIO stock?

You can check MBIO's fair value in chart for subscribers.

Is Mustang Bio Inc a good stock to buy?

The fair value guage provides a quick view whether MBIO is over valued or under valued. Whether Mustang Bio Inc is cheap or expensive depends on the assumptions which impact Mustang Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBIO.

What is Mustang Bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, MBIO's PE ratio (Price to Earnings) is -0.27 and Price to Sales (PS) ratio is 11.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MBIO PE ratio will change depending on the future growth rate expectations of investors.